Pluto Bioinformatics

GSE116237: Towards minimal residual disease-directed therapy in melanoma

Bulk RNA sequencing

Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics, yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD we applied single-cell RNA-sequencing to malignant cells isolated from BRAF-mutant patient-derived xenograft (PDX) melanoma cohorts exposed to concurrent RAF/MEK-inhibition. SOURCE: Sara AibarLaboratory of Computational Biology VIB-KU Leuven